A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- 04 Jun 2019 Trial design for two phase II studies including this study presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 18 Mar 2019 Rationale and protocol of NCT03370718 and NCT03612232 studies were presented at the 101st Annual Meeting of the Endocrine Society.
- 07 Feb 2019 Planned End Date changed from 1 Feb 2020 to 29 Feb 2020.